- CNBC•5 minutes ago
Shares of Teva Pharmaceuticals fell as much as 6 percent on Wednesday after the U.S. Patent Office invalidated two of the company's patents.
- Motley Fool•55 minutes ago
A patent review board rules that claims on Teva Pharmaceuticals' three-times-weekly version of Copaxone aren't patentable.
- TheStreet.com•2 hours ago
Teva was stock was trading sharply lower this afternoon after aspects of its patent for multiple sclerosis drug Copaxone were determined invalid.
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||52.00 x 3100|
|Ask||52.19 x 800|
|Day's Range||49.87 - 53.96|
|52wk Range||48.01 - 66.55|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.49|
|Avg Vol (3m)||5,464,343|
|Dividend & Yield||1.36 (2.54%)|